A ugmentation of immune effector functions by the infusion of T cells selected or engineered for tumor reactivity represents a potentially highly specific modality for the treatment of cancer. In the last decade, a new approach has been developed by genetically engineering T cells to express chimeric immunoglobulin-T-cell receptors (IgTCR) (''designer T cells'') that endow the T cells with antitumor specificity based on the expression of antigen by cancer cells. As killing is MHC-unrestricted, the approach offers a general therapy for all patients. [1] [2] [3] In one such application, we created anti-carcinoembryonic antigen (CEA) designer T cells by fusing the antigen-binding portion of an anti-CEA antibody MN-14 to the zeta chain of TCR-CD3 complex (Fig 1) . 4 These designer T cells combine the specificity of the anti-CEA antibody with the cytotoxic potency of T cells to specifically kill the CEA-expressing tumor cells in vitro 4, 5 and inhibit the CEA-expressing tumor growth in animal models (unpublished data).
CEA is one of the best characterized human tumorassociated antigens and is expressed on a broad range of adenocarcinomas: on tumors in 60-94% of patients with metastatic and recurrent colorectal cancer, 60% of women with metastatic breast cancer, and 430% of patients with cancer of the lung, liver, pancreas, head and neck, bladder, cervix, and prostate. [6] [7] [8] The approach of anti-CEA designer T cells has the potential to treat CEA-positive cancers by adoptive immunotherapy, for which early ongoing clinical trial results are encouraging. 2 In this report, we demonstrate a novel type of molecule for use in selective identification and activation of IgTCRmodified T cells. This involves the conjugation of an antigen or antigen fragment to the Fc domain of immunoglobulin (Ag-Fc). Several advantages derive from the creation of such an Ag-Fc molecule: 1. Ag-Fc protein is simple and economical to produce in large scale, whereas obtaining purified natural antigen may often be problematic or expensive. 2. Ag-Fc provides a ready means for detection of the expression of IgTCR chimeric receptors on the modified T-cell surface. Typically, an anti-idiotype antibody against the IgTCR 4,9 or anti-tag antibody 10 was used. It is time consuming and often problematic to make an anti-idiotype antibody, and insertion of a ''tag'' epitope in the IgTCR chimeric receptor may result in increased immunogenicity of the IgTCR molecule in vivo and may perturb the IgTCR structure for antigen binding. 3. Ag-Fc can be used as a selective ex vivo expansion agent. For a successful adoptive immunotherapy, it is crucial to obtain IgTCRmodified T cells in large scale (up to 10 11 cells), whereas T-cell modification with IgTCR is often inefficient with low percentages of modified cells. By selectively activating those modified cells with immobilized Ag-Fc, the modified cell fraction can be induced to expand to large numbers of designer T cells. 4. Ag-Fc can be applied as a selective in vivo expansion and activating agent. Fc receptor present on monocytes can bind to and crosslink Ag-Fc bound to IgTCR þ T cells in vivo leading to their activation and selective proliferation. 5. Ag-Fc will have a long in vivo survival. The immunoglobulin Fc portion prevents the rapid renal clearance of the fusion protein for in vivo use and substantially prolongs the serum half-life of the administered fusion protein.
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It is our objective to make a preliminary evaluation of this strategy by using CEA-Fc to identify anti-CEA IgTCR transduced T cells and to stimulate their specific expansion. To construct the CEA-Fc fusion protein, the region III (A3B3) of CEA was coupled with the Fc portion of human IgG. The A3B3 region of CEA contains the epitope that binds with the anti-CEA antibody, MN-14. The Fc portion of human IgG antibody provides a domain for binding with anti-human IgG antibodies for detection as well as for crosslinking with peripheral blood mononuclear cells (PBMCs) by binding with the Fc receptors on the PBMCs surface.
Materials and methods

Testing of MN-14 epitope location
CEA cDNA and its derived hybrid construct, NC-3 cDNA, consisting of the three amino-terminal Ig-like domains of NCAM-125 linked to the complete A3B3 and carboxy-terminal domains of CEA, were inserted into the expression vector p91023B and were cotransfected with pSV2Neo into CHO cells 12 or LR-73 cells (a CHO derivative), 13 respectively. Similarly, cDNAs of CEA-CAM1-4L (formerly BGPa), which contains a CEA A1B1A2-like region and CEACAM6 (formerly NCA), which contain a CEA A1B1-like region, were cloned into p91023B and cotransfected with pSV2Neo into LR-73 cells. G418-resistant colonies were selected, pooled and FACS-sorted for relatively high levels of expression, as previously described.
14 Fluorescence-activated cell sorting (FACS) expression profiles were then obtained by treatment of cell suspensions with 16 mg/ml humanized MN-14 or 100 mg/ml anti-CEA mAb J22 or no primary antibody (control) followed by fluorescein (FITC)-conjugated secondary antibody, and analyzed using a Becton Dickinson FACScan instrument, as described previously. 14 
CEA-Fc expression plasmid construction
The coding sequence for the A3B3 region of CEA was amplified by polymerase chain reaction (PCR) using the Advantage HF 2 PCR kit (Clontech, Palo Alto, CA) from a plasmid (IMAGE clone ID: 587150) containing the fulllength human CEA cDNA sequence obtained from American Type Culture Collection (ATCC, Mannassas, VA). The primers used for PCR were as follows: forward primer: 5 0 -ATCGGTACCGCGGAGCTGCCCAAGCC-CTCCATC-3 0 incorporating a KpnI restriction enzyme site; backward primer: 5 0 -ATCGGATCCGCAGATG-CAGAGACTGTGATGCTC-3 0 incorporating a BamHI restriction enzyme site. The amplified PCR product was cut by KpnI and BamHI and inserted into the corresponding site of Signal pIgplus plasmid (R&D system, Abingdon, UK), generating the CEA-Fc expression plasmid, Signal pIgplus-CEA. Bidirectional DNA sequencing was performed to confirm the correctness of the Figure 1 Schematic representation of IgTCR. Antibody V regions were engineered to create a single-chain variable region fragment (sFv) and then linked to the signaling portion of z chain of T-cell receptor, with an intervening spacer derived from the hinge portion of CD8a. CEA-Fc protein production and purification CHO-K1 cell transfectants were grown to confluence in four 162-cm 2 flasks in 50 ml CHO-K1 cell medium for 4 days, cell culture supernatants were collected every 24 hours. The supernatant was tested by enzyme-linked immunosorbent assay (ELISA) and Western blot for CEA-Fc fusion protein expression. The CEA-Fc fusion protein was purified by passing the CHO-K1 supernatant through a Protein A-sepharose affinity column (Amersham Pharmacia Biotech, Uppsala, Sweden). CEA-Fc was eluted with 0.1 M sodium citrate, pH 4.0. Column fractions were neutralized with 1 M Tris-HCl, pH 9.0, and tested by Western blot analysis for positive fractions. The positive fractions were collected, dialyzed against phosphate-buffered saline (PBS), and concentrated with a Centriprep-30 concentrator (Amicon, Beverly, MA).
ELISA
EIA/RIA 96-well flat bottom plates (Corning Inc., Corning, NY) were precoated with 10 mg/ml goat antihuman IgG H þ L antibodies (Bethyl, Montgomery, TX) in PBS overnight at 41C. The wells were blocked with 4% nonfat dry milk in PBS for 30 minutes at 371C. Samples were diluted 1:1 in PBS and added to wells for 1 hour at 371C. As for detection of the Fc portion in the CEA-Fc fusion protein, horseradish peroxidase (HRP)-conjugated goat anti-human IgG Fc antibody (Caltag laboratories, Burlingame, CA) was added at a dilution of 1:1000 in 1% nonfat dry milk in PBS with 0.05% Tween for 1 hour at 371C. For detection of the A3B3 region of CEA in the CEA-Fc fusion protein, mouse anti-human CEA monoclonal antibody MN-14 (gift from Dr Hans Hansen, Immunomedics, Morris Plains, NJ) was added at 1 mg/ml in 1% nonfat dry milk in PBS with 0.05% Tween for 1 hour at 371C, followed by incubation with HRP-conjugated goat anti-mouse IgG antibody (Caltag Laboratories) at a dilution of 1:1000 in 1% nonfat dry milk in PBS with 0.05% Tween for 1 hour at 371C. The ELISA was then developed with o-phenylenediamine dihydrochloride (Sigma Chemical Co., St Louis, MO) and read at 490 nm. PBS was used for all washes.
Western blot assays
For detection of CEA-Fc, samples in reduced and nonreduced conditions were run on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels and electrotransferred to nitrocellulose membranes. The membranes were blocked with 5% nonfat dry milk in Tris-buffered saline (20 mM Tris/500 mM NaC1, pH 7.5) for 1-2 hours. Membranes were washed with TTBS (0.05% Tween-20 in Tris-buffered saline), and HRPconjugated goat anti-human IgG Fc antibody was added at a dilution of 1:1000 for 1 hour (for Fc detection) or mouse anti-human CEA monoclonal antibody MN-14 was added at 1 mg/ml for 1 hour, followed by incubation with HRP-conjugated goat anti-mouse IgG antibody at a dilution of 1:1000 for 1 hour (for CEA A3B3 region detection), all in 1% nonfat dry milk in TTBS. The membrane was developed with enhanced chemiluminescence reagent (Amersham, England, UK) and exposed to X-ray film for 5-60 seconds. All washes were performed with TTBS.
For detection of anti-CEA IgTCR by CEA-Fc, transduced or untransduced Jurkat T cells were lysed in cell lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 0.02% NaN 3 , 0.1% SDS, 1% Triton X-100, 100 mg/ml PMSF) and were run on 12% SDS-PAGE and electrotransferred to nitrocellulose membranes. The membranes were blocked and washed as above. Purified CEA-Fc was added at 1 mg/ml for 1 hour, followed by incubation with HRP-conjugated goat anti-human IgG Fc antibody at a dilution of 1:1000 for 1 hour, each in 1% nonfat dry milk in TTBS and washed as above. The membrane was developed and exposed to X-ray film as above.
Transduction of T cells with anti-CEA IgTCR
A retroviral vector MFG-anti-CEA IgTCR expressing anti-CEA IgTCR chimeric receptor was constructed and packaged in PG13 retroviral producing cells as previously described. 4, 5, 15 Viral supernatant was harvested and used to transduce a Jurkat T-cell line (ATCC) and activated human T cells. For making the Jurkat T cells stably expressing the anti-CEA IgTCR, 10 6 Jurkat T cells were transduced in 5 ml viral supernatant with 10 mg/ml protamine sulfate (Fujisawa USA, Deerfield, IL) and were centrifuged at 1000 g for 1 hour at 321C. The procedure was repeated three times. After transduction, Jurkat T cells were expanded in growth medium (RPMI 1640 with 10% FBS, 20 U/ml penicillin, and 20 mg/ml streptomycin) and FACS was performed by using a rat anti-MN-14 anti-idiotype antibody WI2 (Immunomedics, Morris Plains, NJ) to obtain the anti-CEA IgTCRpositive population. For transducing the activated human T cells, PBMCs from normal blood were cultured and activated with 100 ng/ml mouse anti-human CD3 antibody OKT3 (Ortho Biotech, Raritan, NJ) for 3 days, and cells were transduced as previously described. 4 
Flow cytometric analyses
Cell surface expression of anti-CEA IgTCR on Jurkat T cells or activated human T cells was determined by flow cytometry with either WI2 (Immunomedics, Morris Plains, NJ) or purified CEA-Fc. Cells were incubated with WI2 or CEA-Fc in 50 ml binding buffer (RPMI 1640 containing 10% horse serum) for 30 minutes at 41C with mixing. The cells were then washed with PBS and incubated under the same conditions with phycoerythrin (PE)-conjugated goat anti-mouse IgG (Caltag Laboratories) or PE-conjugated goat anti-human IgG (Caltag Laboratories), respectively. After two washes, the samples were analyzed on a Coulter Epics XL-MCL flow cytometer (Coulter Electronics, Miami, FL). For determining the expression of CD69 on Jurkat T cells, cells were incubated with PE-Cy5 (Tri-color, TC)-conjugated mouse anti-human CD69 antibody (Caltag Laboratories). The incubation and washing conditions were the same as above.
T-cell activation assays
Activation using soluble antigens. Anti-CEA IgTCRmodified or unmodified Jurkat T cells (10 5 ) were cultured with 0.1 mg/ml soluble bovine serum albumin (BSA), OKT3, CEA (Calbiochem, San Diego, CA), or purified CEA-Fc in a 96-well plate. After overnight culture, cells were harvested and cell activation was monitored by measuring the expression of CD69 on the cell surface.
Activation using plate-bound antigens. High-binding tissue culture plates (96-well) were coated with 5 mg/ml BSA, OKT3, CEA, or purified CEA-Fc by incubation overnight in PBS, followed by washing with fresh medium. Anti-CEA IgTCR-modified or unmodified Jurkat T cells (10 5 ) were added to each well and centrifuged to the bottom of the plate. After overnight culturing, cells were harvested from wells by vigorous pipetting to remove bound cells from plate surface and to create a single-cell suspension. Cell activation was monitored by CD69 expression.
Activation using monocyte-bound antigens. Human PBMCs were isolated from normal blood by centrifugation over Histopaque-1083 (Sigma Chemical) and cultured in flask with RPMI 1640 medium with 10% FBS overnight. Adherent monocytes were collected and labeled with 0.01 mM carboxyfluorescein diacetate succinimidyl ester (CFSE) (Molecular Probes, Eugene, OR) for 10 minutes. The CFSE-labeled monocytes were mixed with anti-CEA IgTCR-transduced or untransduced Jurkat T cells at a ratio of 10:1 and the cell mixtures were cultured in the presence of 0.1 mg/ml or indicated concentration of BSA, OKT3, CEA, or purified CEAFc overnight. Cells were harvested and tested for CD69 expression gated on CFSE-negative Jurkat cells.
CEA-Fc induced specific T-cell expansion assays
Anti-CEA IgTCR-transduced activated human T cells (10 6 ) were stimulated with 0.01 mg/ml BSA or CEA-Fc without or in the presence of 5 Â 10 6 human PBMCs for 10 days in a 24-well plate. To monitor the specific expansion of anti-CEA IgTCR-transduced T cells, cells were harvested at day 5 or day 10 and analyzed by flow cytometry with staining by a PE-conjugated WI2 antibody.
Results
Epitope identification
CEA belongs to the immunoglobulin supergene family [16] [17] [18] and is comprised of a glycophosphoinositol-linked Mr 180,000-220,000 glycoprotein of 668 amino-acid residues. CEA consists of five regions: an IgV-like N-terminal region of 108 residues, three highly similar Ig I-like repetitive regions (Repeats I, II, and III, each consisting of a pair of subdomains A1 and B1, A2 and B2 and A3 and B3, respectively) of 178 residues each, and a highly hydrophobic C-terminal region of 26 residues that is removed during processing to allow attachment of the GPI anchor. 17, 19, 20 In the plan to make the Fc fusion protein, we considered that the size of product would be unwieldy if we used intact CEA to make a molecule of the form CEA 2 -Fc (ca. 450 kDa). We therefore sought to determine if a smaller region of CEA that contained the MN-14 binding epitope could be identified with which to prepare a new molecule of more manageable size.
The epitope-containing domain was determined by binding MN-14 to transfectant cells expressing CEA derivatives and various CEA family members (Fig 2) . MN-14 bound well to intact CEA transfectants of the Lec-1 mutant of CHO cells (Fig 2a) , which produces severely truncated Asn-linked sugar structures on all glycoproteins.
12 MN-14 thus binds to a protein epitope on CEA rather than carbohydrate. MN-14 also bound well to NC-3-expressing LR-73 cells (derived from CHO). Since the NC-3 construct contains only the A3B3 domain of CEA with its GPI anchor, this result places the MN-14 epitope within the A3B3 domain (Fig 2b) . Consistent with this conclusion, MN-14 did not bind to CEA family members CEACAM1 or CEACAM6 (Fig 2c, d) , both of which lack CEA-like A3B3 domains. 21 Also, MN-14 was previously placed in the Primus class III, CEA-specific monoclonal antibodies that include some demonstrated to bind selectively in the A3B3 region. 22 Additional tests with an NC-A3 construct (J Shively, personal communication) further narrowed the MN-14 epitope to the A3 subregion.
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The normal immunoglobulin structure has one constant domain between the hinge of the Fc and the V region that actively binds antigen. To approximate this geometry in our engineered molecule, the CEA-Fc was designed to include the entire RIII (A3B3) region, in which the B3 domain would have the role of spacer, to separate the A3 epitope-containing domain from the Fc hinge. It is noted, however, that numerous chimeric molecules with shorter, single domains have been successfully engineered onto human Fc domains without steric interference, 23 and it is thus likely that an A3-Fc construct would function as well as the A3B3-Fc. A specific comparison was not designed as part of this study.
Construction, expression, and characterization of CEA-Fc
To create the CEA-Fc fusion protein, cDNA coding for the A3B3 region of CEA was fused with the cDNA coding for the Fc part of human IgG1 (Fig 3) . The newly constructed CEA-Fc fusion protein consists of a total of 472 amino-acid residues including 17 residues of the CD33 signal peptide, 183 residues of CEA A3B3 region, 232 residues of IgG1 Fc, a 7-residue linker between the CD33 signal peptide and CEA A3B3 and a 9-residue linker between CEA A3B3 and IgG1 Fc. The mature CEA-Fc in secreted form has 455 amino-acids residues with a monomeric protein with molecular weight of 44,308 Da.
To express CEA-Fc, CHO-K1 cells were transfected with the Signal pIgplus-CEA plasmid and selected for stable transformants. The supernatants from transformants were analyzed by ELISA for high expressors. The presence of Fc and CEA components was verified (Fig 4A) . (The high background of 0.27 in the medium control is due to crossreactivity of MN-14 with BSA in the culture medium. See figure legend.) These results were confirmed by Western blot (Fig 4B) that established the presence of CEA and Fc reactivities and appropriate product sizes. Specific protein bands at about 170 and 85 kDa were detected in the CHO supernatant under nonreducing and reducing conditions, respectively, indicating that the CEA-Fc protein was expressed in a disulfide-linked dimer form. Since Fc is normally a dimeric molecule of CH2-CH3 domains, the native form is represented as CEA 2 -Fc. Comparing the apparently increased molecular weight of 85 kDa for the reduced form versus the 44 kDa mass deduced from the aminoacid sequence, a high degree of glycosylation of the CEAFc is inferred.
Taken together, the Western blot results confirmed the ELISA results that CEA-Fc fusion protein was expressed in the transfected CHO supernatant. The CEA-Fc fusion protein was purified over a Protein A affinity column, dialyzed against PBS and concentrated for further use.
Detection of MN-14 antibody and anti-CEA IgTCR by CEA-Fc
To determine whether the CEA-Fc fusion protein exhibits the native CEA A3B3 region binding activity with the MN-14 antibody and its single-chain Fv (sFv) derivative 
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in the anti-CEA IgTCR, Western blot and flow cytometric assays were performed (Fig 5) . Western blot (Fig 5a) with CEA-Fc successfully detected MN-14 antibody (lane 1) and anti-CEA IgTCR chimeric receptor expressed on transduced Jurkat T cells (lane 4). CEA-Fc was also successfully applied in flow cytometry (Fig 5b) , showing CEA-Fc detection of the expression of anti-CEA IgTCR chimeric receptors on transduced Jurkat T cells that is equivalent to that with a derived anti-idiotype antibody. In conclusion, the CEA-Fc effectively detects MN-14 antibody and the anti-CEA IgTCR chimeric receptor.
Activation of anti-CEA IgTCR-transduced Jurkat T Cells by CEA-Fc
To determine if CEA-Fc can be used as an antigen to selectively activate the anti-CEA IgTCR-modified Jurkat T cells, CEA-Fc was tested in three different forms: soluble, plate-bound, and monocyte-bound. As soluble were stained with either CEA-Fc and followed by staining with a secondary PE-conjugated goat anti-human IgG antibody (solid line) or mouse anti-idiotype antibody (WI2) against MN-14 IgTCR and followed by staining with a secondary PE-conjugated goat antimouse IgG antibody (solid line). Cells stained with a negative control antibody and followed by staining with the same secondary antibody were used as negative control (dashed line).
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antigen, neither CEA nor CEA-Fc nor control antigen BSA activated either unmodified or anti-CEA IgTCRmodified Jurkat T cells (Fig 6a) . The control anti-CD3 OKT3 antibody activated Jurkat T cells in soluble state at a concentration as low as 10 ng/ml, while the CEA-Fc in soluble form did not activate the anti-CEA IgTCRmodified Jurkat T cells even with 10,000 ng/ml (data not shown). However, as plate-bound antigen, both CEA and CEA-Fc were equal to OKT3 in selective activation of anti-CEA IgTCR-modified Jurkat T cells but not unmodified Jurkat T cells (Fig 6b) .
In the presence of monocytes, the soluble CEA-Fc could selectively activate the anti-CEA IgTCR-modified Jurkat T cells, equal to OKT3, whereas soluble CEA could not (Fig 6c) . This difference in CEA-Fc and CEA was due to the binding and crosslinking of the CEA-Fc by Fc receptors that are expressed on the surface of monocytes. The control anti-CD3 OKT3 antibody could activate Jurkat T cells under all conditions -albeit also better under conditions of immobilization -through the normally expressed endogenous TCR, while BSA could not (Fig 6c) . 
To determine the optimal concentration of CEA-Fc that can be used in monocytes-bound form for activation of anti-CEA IgTCR-modified T cells, CEA-Fc at different concentrations (10-1000 ng/ml) in the presence of monocytes was applied to activate the anti-CEA IgTCR-modified Jurkat T cells (Fig 7) . The anti-CEA IgTCR-modified Jurkat T cells could be activated over broad range of CEA-Fc concentrations, to as low as 10 ng/ml.
Selective expansion of Anti-CEA IgTCR-modified T cells by CEA-Fc activation
It was a major objective of this research to use CEA-Fc to stimulate the specific clonal expansion of anti-CEA IgTCR-transduced T cells in a mix of modified and unmodified cells. As proliferation is a key feature for the clinical applications of this molecule, immortal cell lines such as Jurkat could not be applied. Instead, we employed normal human T cells to test this hypothesis. The infection of T cells with retrovirus containing IgTCR requires prior activation and division of the recipient T cells (Materials and methods). This expansion, once initiated, typically proceeds over a period of a month with increases of up to 100-fold or more in total cell number. The fraction of modified T cells over this period typically is stable throughout the ex vivo expansion period. If selective stimulation could be achieved, this modified fraction would increase during the expansion period.
The experimental design was to restimulate the modified T cells with CEA-Fc or BSA as negative control, without or with monocytes. Normally, Signal 1 through the T-cell receptor by itself will induce activation-induced cell death (AICD), 15 leading to selective depletion of the IgTCR-modified T cells. However, we considered that the B7 antigen present on monocytes could present costimulatory Signal 2 in conjunction with the IgTCR (Signal 1) to prevent AICD and lead to selective expansion.
This experiment started with T cells that were B8% transduced with anti-CEA IgTCR chimeric receptors. Without monocytes, there is no receptor crosslinking and no Signal 1, and the percentage of anti-CEA IgTCRmodified T cells remained relatively unchanged for either CEA-Fc or BSA (Fig 8a) . In the presence of monocytes, however, CEA-Fc, but not BSA, stimulated an increase in the proportion of anti-CEA IgTCR-transduced T cells, from the original 8.5% to 18% at day 5 and further increased to 28% at day 10 after restimulation (Fig 8b) . Since unmodified and modified T cells are both initially expanding equally in the culture, these data demonstrate a selective acceleration of the proliferation of the IgTCRmodified portion of the cell population after CEA-Fc stimulation, with a rate constant estimated as approximately 170% of baseline (calculations not shown).
These results indicate that the CEA-Fc can be successfully applied to induce specific clonal expansion of anti-CEA IgTCR-modified T cells in the presence of monocytes. This final feature potentially offers the opportunity to expand such cells in vivo as well as ex vivo in human therapeutic applications.
Discussion
We describe here the generation of a functional CEA-IgG Fc fusion protein. Our data indicate that CEA-Fc is in disulfide-linked dimer form (CEA 2 -Fc), and, like its parent CEA, CEA-Fc is highly glycosylated. The disulfide-linked dimer form is presumed to be due to crosslinking of cysteines in the hinge of Fc portion of the CEA-Fc corresponding to the native immunoglobulin G1 that contains the same Fc portion.
MN-14 is a well-characterized medium-affinity mouse anti-human CEA antibody 22, 24 that has been widely used for diagnosis and treatment of various CEA-expressing human cancers. 24, [24] [25] [26] [27] [28] [29] [30] [31] We show here that MN-14 binds an epitope in region III (A3B3) of the CEA molecule, consistent with its designation as a Class III anti-CEAspecific monoclonal antibody. 22 In this study, we constructed a CEA-Fc fusion protein that consists of the same A3B3 region of CEA and the Fc region of IgG1. Our results indicate that the CEA-Fc binds specifically to MN-14 antibody but also to the sFv IgTCR chimeric receptor derived from this antibody. Therefore, the CEAFc fusion protein produced in this report may be used for the purpose of identifying the expression of anti-CEA IgTCR chimeric receptor on the transduced T cells by Western blot and flow cytometric analysis. This is an important benefit to all designed clinical trials to be able to document the fraction of modified cells during ex vivo manipulations and to support pharmacokinetic studies of the infused T cells. Furthermore, the availability of an Ag-Fc molecule bypasses the need to prepare an antiidiotype antibody that in the past has typically been required to conduct such analyses. The alternative strategy has been to incorporate epitope ''tag'' sequences into the IgTCR chimeric molecule for detection with epitope-specific antibodies. The Ag-Fc molecule bypasses such need with its attendant risks of structural disruption in the IgTCR and potential for increased immunogenicity in clinical applications. The fact that the product is entirely human in sequence (human CEA, human Fc) means that it can safely be used in humans with a low likelihood of immunogenicity.
Our previous studies have shown that anti-CEA IgTCR-modified T cells can kill CEA-expressing tumor cells in vitro, 4,5 prevent tumor formation in nude mice (unpublished results) and exhibit limited antitumor activity in human clinical phase I trial. 2 A major challenge for using the anti-CEA IgTCR-modified T cells for adoptive immunotherapy is how to enhance the survival and expansion of the modified T cells both in vitro and in vivo. Currently, the anti-CEA IgTCR-modified T cells are produced by multiple ex vivo infections of peripheral blood T lymphocytes stimulated by anti-CD3 antibody, alone or in combination with anti-CD28 antibody, with moderate resulting percentages of modified T cells (10-70%) and limited expansions. It is crucial to obtain IgTCR-modified T cells in large scale (up to 10 11 cells) for a successful adoptive immunotherapy. 32 It has been demonstrated that, under appropriate conditions, activated T cells can be reactivated to proliferate by the cognate antigen. 15, 33 An objective of this study was to induce the specific clonal expansion of anti-CEA IgTCR-modified T cells by stimulating the transduced T cells with CEA-Fc. Our results showed that the CEA-Fc will specifically activate anti-CEA IgTCRmodified T cells in the presence of monocytes in vitro and lead to their selective expansion. This selective expansion occurs by supplying Signal 1 through IgTCR recognition of CEA-Fc ''immobilized'' in an activating configuration by monocyte FcR, plus costimulatory Signal 2 from B7 on monocytes delivered to the CD28 coreceptor on T cells, which suppresses AICD. This result implies the possibility of using the CEA-Fc to activate the anti-CEA IgTCR-modified T cells to proliferate in vivo in humans as well, for which it could potentially be a useful ancillary therapeutic product.
To summarize, a CEA-Fc fusion protein was constructed and produced in this study. The CEA-Fc was effective in detecting the expression of anti-CEA IgTCR chimeric receptors on modified T cells, and it was shown to selectively activate the modified T cells to an accelerated proliferation and enrichment under certain conditions in vitro. The successful construction, expression and specific T-cell amplification mediated by the CEA-Fc fusion protein encourage consideration of this and other Ag-Fc molecules for their possible clinical utility, both for ex vivo and in vivo applications.
